The Randomized, Controlled Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Lung Adenocarcinoma Patients With Wild-Type EGFR

Trial Profile

The Randomized, Controlled Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Lung Adenocarcinoma Patients With Wild-Type EGFR

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2016

At a glance

  • Drugs Apatinib (Primary)
  • Indications Adenocarcinoma; Lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Feb 2016 Status changed from not yet recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 14 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top